Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects identifier:
NCT04030559 (

High-risk localized prostate cancer

Study Contact Information:

For additional information, contact:
Dr. Marc Dall'Era by phone: 916-734-3771
or by email: [email protected]

About the Study

This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.

What the Study Entails

Study Site

Sacramento, CA
University of California Davis Comprehensive Cancer Center 
Contact: Dr. Marc Dall'Era by phone: 916-734-3771 or by email: [email protected]

This Study is Open To:

People diagnosed with prostate cancer who meet the following criteria:

This Study is Not Open To:

People with the following may not participate:

Check or study contact for a full list of exclusion criteria. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.